Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call
ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019. The preliminary results have not been audited and are subject to change.
Patient Treatments with ViewRay’s MRIdian Linac Begin in New England
Joint Cancer Program in Boston First in New England to Offer MRI-Guided Radiation Therapy
Penn State Health Enters into Master Purchase Agreement with ViewRay for MRIdian® Systems
Immediate order of one system with ability to purchase an additional three systems by Penn State Health.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy